Overview

A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)

Status:
Completed

Trial end date:
2019-06-18

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.
Neurocrine Biosciences

Collaborator:

Takeda

Treatments:

Ketamine